Literature DB >> 24587621

Exploring alternative treatments for Helicobacter pylori infection.

Guadalupe Ayala1, Wendy Itzel Escobedo-Hinojosa1, Carlos Felipe de la Cruz-Herrera1, Irma Romero1.   

Abstract

Helicobacter pylori (H. pylori) is a successful pathogen that can persist in the stomach of an infected person for their entire life. It provokes chronic gastric inflammation that leads to the development of serious gastric diseases such as peptic ulcers, gastric cancer and Mucosa associated lymphoid tissue lymphoma. It is known that these ailments can be avoided if the infection by the bacteria can be prevented or eradicated. Currently, numerous antibiotic-based therapies are available. However, these therapies have several inherent problems, including the appearance of resistance to the antibiotics used and associated adverse effects, the risk of re-infection and the high cost of antibiotic therapy. The delay in developing a vaccine to prevent or eradicate the infection has furthered research into new therapeutic approaches. This review summarises the most relevant recent studies on vaccine development and new treatments using natural resources such as plants, probiotics and nutraceuticals. In addition, novel alternatives based on microorganisms, peptides, polysaccharides, and intragastric violet light irradiation are presented. Alternative therapies have not been effective in eradicating the bacteria but have been shown to maintain low bacterial levels. Nevertheless, some of them are useful in preventing the adverse effects of antibiotics, modulating the immune response, gastroprotection, and the general promotion of health. Therefore, those agents can be used as adjuvants of allopathic anti-H. pylori eradication therapy.

Entities:  

Keywords:  Helicobacter pylori; Natural products; Nutraceuticals; Probiotics; Treatment

Mesh:

Substances:

Year:  2014        PMID: 24587621      PMCID: PMC3925854          DOI: 10.3748/wjg.v20.i6.1450

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  205 in total

1.  [Preliminary study of the prevalence of Helicobacter pylori in Tananarive, Madagascar and the antibacterial activity in vitro of 13 Malagasy medicinal plants on this germ].

Authors:  A M Cassel-Beraud; J Le Jan; J C Mouden; M Andriantsoa; R Andriantsiferana
Journal:  Arch Inst Pasteur Madagascar       Date:  1991

2.  Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori.

Authors:  B Peck; M Ortkamp; K D Diehl; E Hundt; B Knapp
Journal:  Nucleic Acids Res       Date:  1999-08-15       Impact factor: 16.971

3.  Polyphenols reduce gastritis induced by Helicobacter pylori infection or VacA toxin administration in mice.

Authors:  P Ruggiero; F Tombola; G Rossi; L Pancotto; L Lauretti; G Del Giudice; M Zoratti
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis.

Authors:  S J Hessey; J Spencer; J I Wyatt; G Sobala; B J Rathbone; A T Axon; M F Dixon
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

Review 5.  pathogenesis of Helicobacter pylori-induced gastric inflammation.

Authors:  D A Israel; R M Peek
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

6.  A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori.

Authors:  Carl-Fredrik Flach; Natascha Svensson; Margareta Blomquist; Annelie Ekman; Sukanya Raghavan; Jan Holmgren
Journal:  Vaccine       Date:  2010-12-13       Impact factor: 3.641

7.  Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.

Authors:  W G Metzger; E Mansouri; M Kronawitter; S Diescher; M Soerensen; R Hurwitz; D Bumann; T Aebischer; B-U Von Specht; T F Meyer
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

8.  Allyl-thiosulfinates, the bacteriostatic compounds of garlic against Helicobacter pylori.

Authors:  Pablo Cañizares; Ignacio Gracia; Luis A Gómez; Carlos Martín de Argila; Daniel Boixeda; Antonio García; Luis de Rafael
Journal:  Biotechnol Prog       Date:  2004 Jan-Feb

9.  Decreased epithelial cytokine responses in the duodenal mucosa of Helicobacter pylori-infected duodenal ulcer patients.

Authors:  E Strömberg; A Edebo; A-M Svennerholm; C Lindholm
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

10.  Anti-Helicobacter pylori activity of plants used in Mexican traditional medicine for gastrointestinal disorders.

Authors:  Israel Castillo-Juárez; Violeta González; Héctor Jaime-Aguilar; Gisela Martínez; Edelmira Linares; Robert Bye; Irma Romero
Journal:  J Ethnopharmacol       Date:  2008-12-27       Impact factor: 4.360

View more
  27 in total

Review 1.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

Review 2.  Friend and foe: factors influencing the movement of the bacterium Helicobacter pylori along the parasitism-mutualism continuum.

Authors:  Derek Lin; Britt Koskella
Journal:  Evol Appl       Date:  2014-11-20       Impact factor: 5.183

Review 3.  Reactive oxygen species, apoptosis, antimicrobial peptides and human inflammatory diseases.

Authors:  Babatunji Emmanuel Oyinloye; Abiola Fatimah Adenowo; Abidemi Paul Kappo
Journal:  Pharmaceuticals (Basel)       Date:  2015-04-02

4.  Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.

Authors:  Aliakbar Hajaghamohammadi; Seyyed Hossein Safiabadi Tali; Rasoul Samimi; Sonia Oveisi; Amir Mohammad Kazemifar
Journal:  Glob J Health Sci       Date:  2014-08-31

Review 5.  Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.

Authors:  Maria Teresa Mascellino; Barbara Porowska; Massimiliano De Angelis; Alessandra Oliva
Journal:  Drug Des Devel Ther       Date:  2017-07-28       Impact factor: 4.162

6.  Isolation of Abscisic Acid from Korean Acacia Honey with Anti-Helicobacter pylori Activity.

Authors:  SeGun Kim; InPyo Hong; SoonOk Woo; HyeRi Jang; SokCheon Pak; SangMi Han
Journal:  Pharmacogn Mag       Date:  2017-07-11       Impact factor: 1.085

Review 7.  Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy.

Authors:  Farnaz Fahimi; Mohammad Reza Tohidkia; Mehdi Fouladi; Reza Aghabeygi; Naser Samadi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2017-03-30

8.  The Protective Effects of 18β-Glycyrrhetinic Acid on Helicobacter pylori-Infected Gastric Mucosa in Mongolian Gerbils.

Authors:  Donghui Cao; Jing Jiang; Lili You; Zhifang Jia; Tetsuya Tsukamoto; Hongke Cai; Shidong Wang; Zhen Hou; Yue-er Suo; Xueyuan Cao
Journal:  Biomed Res Int       Date:  2016-02-24       Impact factor: 3.411

Review 9.  Biofilm Forming Lactobacillus: New Challenges for the Development of Probiotics.

Authors:  María José Salas-Jara; Alejandra Ilabaca; Marco Vega; Apolinaria García
Journal:  Microorganisms       Date:  2016-09-20

10.  Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori.

Authors:  Rita S Santos; George R Dakwar; Ranhua Xiong; Katrien Forier; Katrien Remaut; Stephan Stremersch; Nuno Guimarães; Sílvia Fontenete; Jesper Wengel; Marina Leite; Céu Figueiredo; Stefaan C De Smedt; Kevin Braeckmans; Nuno F Azevedo
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-08       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.